With third FDA ap­proval, Seat­tle Ge­net­ics plans vir­tu­al launch of metasta­t­ic breast can­cer drug amid coro­n­avirus pan­dem­ic

Seat­tle Ge­net­ics has burst in­to the com­pet­i­tive mar­ket for breast can­cer drugs, with a brain pen­e­trat­ing ther­a­py: Tukysa.

The com­pa­ny — which has two armed an­ti­bod­ies, Ad­cetris and Pad­cev, in its ar­se­nal — se­cured FDA ap­proval for Tukysa on Fri­day, rough­ly four months ahead of the ex­pect­ed de­ci­sion date. The list price for Tukysa will be $18,500/month and $111,000 per course of treat­ment, im­ply­ing an ex­pect­ed du­ra­tion of ther­a­py of about 6 months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER